BMPR2 and pulmonary arterial hypertension: Using the CRISPR-Cas9 system to correct the BMPR2 mutation in PAH iPSC-ECs, the authors demonstrated that correcting the BMPR2 mutation successfully restores the BMPR2 signaling, EC function, and normalized angiogenesis and cell migration upon BMP4 stimulation [140].